Vildagliptin dihydrate
Based on 5 publication(s) in Google Scholar
Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2133364-01-7
- Formule: C17H29N3O4
- Masse moléculaire:339.43
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-10284
Linagliptin
-
HY-14291
Vildagliptin
-
HY-A0023A
Alogliptin
-
HY-13749
Sitagliptin
-
HY-15408
Trelagliptin
-
HY-13749B
Sitagliptin phosphate monohydrate
-
HY-14806A
Teneligliptin hydrobromide
-
HY-15408A
Trelagliptin succinate
-
HY-A0023
Alogliptin Benzoate
-
HY-13233A
Talabostat mesylate
-
HY-10285
Saxagliptin
-
HY-10284R
Linagliptin (Standard)
Publications Citing Use of MedChemExpress (MCE) Vildagliptin dihydrate
More
Customer Validation & Images
-
RT-PCR
-
IF
Activité biologique
|
DPP-4 |
Vildagliptin (10 µmol/kg; orally) significantly decreases glucose excursions and stimulate insulin secretion in obese male Zucker rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male db/db mice (BKS) and wildtype mice[2]
-
Dosage:35 mg/kg
-
Administration:Oral gavage; once daily; for 6 weeks
-
Result:Increased plasma active GLP-1 levels (22.63±1.19 vs. 11.69±0.44).
-
Animal Model:Obese male Zucker rats[1]
-
Dosage:10 µmol/kg (Pharmacokinetic Analysis)
-
Administration:Orally
-
Result:Significantly decreased glucose excursions and stimulate insulin secretion.
Chemical Information
-
CAS No. 2133364-01-7
-
Masse moléculaire 339.43
-
Formule C17H29N3O4
-
SMILES
O[C@@]1(C[C@H](C2)C3)C[C@H]3C[C@@]2(NCC(N4CCC[C@H]4C#N)=O)C1.O.O
-
Synonyms
LAF237 dihydrate; NVP-LAF 237 dihydrate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. [Abstract]2018 Apr 28:420:26-37. PMID: 29409972
Vildagliptin dihydrate purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Apr 28:420:26-37. [Abstract]
Representative images showing visible metastatic nodules in the lungs of mice treated with Vildagliptin and fed an high-fat diet (HFD).
-
Cell Rep
Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells. [Abstract]2023 Feb 28;42(2):112105. PMID: 36807138 -
Int J Mol Sci
Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis. [Abstract]2022 Nov 15;23(22):14101. PMID: 36430582
Vildagliptin dihydrate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Nov 15;23(22):14101. [Abstract]
qPCR Assay. Vildagliptin (5 µM; 0, 6, 12, 24, 48, 72 h) stimulates the expression of IL-6 in HaCaT cells.
-
J Biol Chem
Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding. [Abstract]2018 Dec 7;293(49):18864-18878. PMID: 30291141 -
3 Biotech
Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease via autophagy modulation. [Abstract]2026 Apr;16(4):146. PMID: 41853215
Pureté et documentation
Références
[1]. Cheng Q, et al. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther. 2008 Dec;327(3):683-91. [Content Brief]
[2]. Shen M, et al. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Exp Diabetes Res. 2012;2012:146194. [Content Brief]
[3]. Abdelhamid AM, et al. Vildagliptin/Pioglitazone Combination Improved The Overall Glycemic Control In Type I Diabetic Rats. Can J Physiol Pharmacol. 2018 Mar 6. doi: 10.1139/cjpp-2017-0680. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vildagliptin dihydrate Related Classifications
HY-14291A Related Classifications
Powered by Bioz